Sacubitril/Valsartan in Left Ventricular Assist Device Recipients

Summary

The primary objective of this prospective randomised study is to assess the safety and tolerability of sacubitril/valsartan compared with standard of care used for treating BP in patients that have been implanted with the Heart Mate 3 LVAD (events of special interest - all cause death, right ventricular failure, bleeding events, deterioration in renal function, hyperkalemia, symptomatic hypotension).

Timeline

Start

2021-02-05

Primary completion

2025-02

Completion

2025-02

Publications

• Cikes M, Planinc I, Brugts JJ, Claggett B, Jorde UP, Milicic D, Ruschitzka F, Uriel N, Jakus N, Loncaric F, Puskaric F, Rubis P, van Laake LW, Rudez I, Hegarova M, Mehra M, Solomon SD. Rationale, design, and baseline characteristics of the multicENter, randomized, open-label, parallel group, study to evaluate the use of sacubitril/valsartan in HeartMate 3 left ventricular assist device recipients (ENVAD-HF). J Card Fail. 2026 Feb;32(2):406-418. doi: 10.1016/j.cardfail.2025.07.015. Epub 2025 Aug 14.

Drugs

Indications